REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

REPL Investors with Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, Sept. 16, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to a massive 77% stock price crash after the FDA rejected its application.

Read more at prnewswire.com